New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

Lindsey Duquette

Coordinator, Corporate Partnerships

Lindsey serves as NephCure’s Corporate Partnerships Coordinator and holds a bachelor's degree in political science from Loyola University Maryland. A rare kidney disease patient herself, Lindsey was diagnosed with Nephrotic Syndrome when she was two years old. The disease was later discovered to be Focal Segmental Glomerulosclerosis (FSGS). As a result of lack of treatment options, Lindsey experienced 172 hospitalizations and 22 surgeries over the course of 8 years in a failed effort to save her native kidneys. Lindsey experienced peritoneal and hemodialysis, has been on countless combinations of medications (including prednisone, rituximab, and Cytoxan), and received a living donor kidney transplant in June 2012. Post-transplant life has been transformative, allowing her to pursue her passions of painting, playing several musical instruments, and video games.

Lindsey understands first-hand the journey of a rare disease patient and has dedicated herself to advocating for better healthcare and treatment options for all kidney patients.

Washington DC

Noticias relacionadas

NOTICIAS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NOTICIAS

NephCure Specialist of the Month: Dr. Rupali Avasare

NOTICIAS

Making History on Capitol Hill: Record Advocates Unite for NephCure’s Largest Hill Day Ever

NOTICIAS

NephCure Specialist of the Month: Dr. Fahad Aziz

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.